Full line of Sensus’ SRT products for the non-invasive treatment of non-melanoma skin cancer and keloids now available to MIS Healthcare customers
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a partnership with MIS Healthcare to distribute Sensus’ superficial radiation therapy (SRT) products in the United Kingdom and Ireland. This agreement includes the company’s SRT-100™, SRT-100+™ and SRT-100 Vision™ systems for the treatment of non-melanoma skin cancer and keloids.
“Our new partnership with MIS Healthcare provides Sensus with greater exposure in the United Kingdom and Ireland, and opens new markets for our SRT products. Having received the CE mark for our SRT system in 2011, we look forward to this new opportunity with a highly capable partner and a shared commitment to the highest level of customer service,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.
Each day nearly 600 people are diagnosed with non-melanoma skin cancer in the United Kingdom and Ireland. The SRT family of products offers them a new treatment option that is non-invasive and painless. In addition, unlike Mohs surgery, with SRT there is no post-procedure downtime for recovery and healing.
“The Sensus team looks forward to working with MIS Healthcare to expand the reach of our innovative products for the non-invasive treatment of non-melanoma skin cancer and keloids,” said Benson Suen, Vice President of International Sales at Sensus Healthcare. “MIS Healthcare has an excellent reputation as a distributor of the highest quality medical devices, and brings a broad and growing network of relationships within the public and private healthcare sectors to support an effective market entry.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.